Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares IssuedShort-Term Debt repayments
Ratios

BeOne Medicines (BEIGF) Cost of Revenue (2017 - 2025)

BeOne Medicines (BEIGF) has disclosed Cost of Revenue for 9 consecutive years, with $142.4 million as the latest value for Q4 2025.

  • Quarterly Cost of Revenue fell 11.3% to $142.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $668.5 million through Dec 2025, up 12.53% year-over-year, with the annual reading at $668.5 million for FY2025, 12.53% up from the prior year.
  • Cost of Revenue for Q4 2025 was $142.4 million at BeOne Medicines, down from $196.5 million in the prior quarter.
  • The five-year high for Cost of Revenue was $196.5 million in Q3 2025, with the low at $32.7 million in Q1 2021.
  • Average Cost of Revenue over 5 years is $104.7 million, with a median of $96.1 million recorded in 2023.
  • The sharpest move saw Cost of Revenue soared 153.46% in 2021, then decreased 11.3% in 2025.
  • Over 5 years, Cost of Revenue stood at $48.5 million in 2021, then soared by 51.45% to $73.5 million in 2022, then soared by 43.95% to $105.8 million in 2023, then soared by 51.71% to $160.6 million in 2024, then fell by 11.3% to $142.4 million in 2025.
  • According to Business Quant data, Cost of Revenue over the past three periods came in at $142.4 million, $196.5 million, and $164.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.